Tissue responses to hexyl 5-aminolevulinate-induced photodynamic treatment in syngeneic orthotopic rat bladder cancer model: Possible pathways of action

Journal of Biomedical Optics

Volumn 16, Issue 2, 2011, Pages

  Arum, Carl Jørgen ^a,b   Gederaas, Odrun A ^b   Larsen, Eivind L P ^b   Randeberg, Lise L ^b   Hjelde, Astrid ^b   Krokan, Hans E ^b   Svaasand, Lars O ^b   Chen, Duan ^b   Zhao, Chun Mei ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Apoptosis; Autophagy; Immune system; Photodynamic therapy; Rats

Indexed keywords

APOPTOTIC; AUTOPHAGY; BIOINFORMATICS ANALYSIS; BLADDER CANCERS; CANCER STEM CELLS; CASPASE-3; GENE EXPRESSION PROFILES; HUMAN BLADDER CANCER; IMMUNE SYSTEMS; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL APOPTOSIS; MITOCHONDRIAL DAMAGE; MONONUCLEAR CELLS; ORTHOTOPIC; PHOTODYNAMIC TREATMENTS; PROLIFERATING CELL NUCLEAR ANTIGENS; T CELL ACTIVATION; T-CELL RECEPTORS; TISSUE RESPONSE; TUMORIGENESIS; UROTHELIUM;

ACTIVATION ANALYSIS; BIOINFORMATICS; CELL DEATH; CELL MEMBRANES; CELL PROLIFERATION; CHEMICAL ACTIVATION; DISEASES; DRUG PRODUCTS; GENE EXPRESSION; MITOCHONDRIA; PLASMONS; RATS; STEM CELLS; TRANSMISSION ELECTRON MICROSCOPY; TUMORS;

PHOTODYNAMIC THERAPY;

RATTUS;

AMINOLEVULINIC ACID;

ANIMAL; ARTICLE; BLADDER TUMOR; DRUG EFFECT; FISCHER 344 RAT; METABOLISM; METHODOLOGY; PHOTOCHEMOTHERAPY; RAT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE;

AMINOLEVULINIC ACID; ANIMALS; CELL LINE, TUMOR; PHOTOCHEMOTHERAPY; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79957817378     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.3536536     Document Type: Article

References (49)

1. D. Raghavan, D. Quinn, D. G. Skinner, and J. P. Stein, "Surgery and adjunctive chemotherapy for invasive bladder cancer," Surg. Oncol. 11(1-2), 55-63 (2002).
2. S. Holmang, H. Hedelin, C. Anderstrom, and S. L. Johansson, "The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years," J. Urol. 153(6), 1823-1826; discussion 1826-1827 (1995).
3. M. Castillo-Martin, J. Domingo-Domenech, O. Karni-Schmidt, T. Matos, and C. Cordon-Cardo, "Molecular pathways of urothelial development and bladder tumorigenesis," Urol. Oncol. 28(4), 401-408 (2010).
4. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Bohle, and J. Palou-Redorta, "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder," Eur. Urol. 54(2), 303-314 (2008).
5. M. C. Hall, S. S. Chang, G. Dalbagni, R. S. Pruthi, J. D. Seigne, E. C. Skinner, J. S. Wolf, Jr., and P. F. Schellhammer, "Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update," J. Urol. 178(6), 2314-2330 (2007).
6. A. B. Alexandroff, A. M. Jackson, M. A. O'Donnell, and K. James, "BCG immunotherapy of bladder cancer: 20 years on," Lancet 353(9165), 1689-1694 (1999).
7. R. F. Bevers, K. H. Kurth, and D. H. Schamhart, "Role of urothelial cells in BCG immunotherapy for superficial bladder cancer," Br. J. Cancer 91(4), 607-612 (2004).
8. S. J. Dovedi and B. R. Davies, "Emerging targeted therapies for bladder cancer: a disease waiting for a drug," Cancer Metastasis Rev. 28(3-4), 355-367 (2009).
9. W. H. Rawls, D. L. Lamm, B. A. Lowe, E. D. Crawford, M. F. Sarosdy, J. E. Montie, H. B. Grossman, and P. T. Scardino, "Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer," J. Urol. 144(6), 1328-1330 (1990).
10. J. A. Gonzalez, B. R. Marcol, and M. C. Wolf, "Complications of intravesical bacillus Calmette-Guerin: a case report," J. Urol. 148(6), 1892-1893 (1992).
11. F. W. Leebeek, R. J. Ouwendijk, A. H. Kolk, A. Dees, J. C. Meek, J. E. Nienhuis, and A. M. Dingemans-Dumas, "Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation," Gut 38(4), 616-618 (1996).
12. J. G. Heiner and M. K. Terris, "Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guerin therapy," Urol. Oncol. 26(2), 137-140 (2008).
13. S. Denzinger, M. Burger, B. Walter, R. Knuechel, W. Roessler, W. F. Wieland, and T. Filbeck, "Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study," Urology 69(4), 675-679 (2007).
14. I. Kausch, M. Sommerauer, F. Montorsi, A. Stenzl, D. Jacqmin, P. Jichlinski, D. Jocham, A. Ziegler, and R. Vonthein, "Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies," Eur. Urol. 57(4), 595-606 (2009).
15. J. A. Witjes, J. P. Redorta, D. Jacqmin, F. Sofras, P. U. Malmstrom, C. Riedl, D. Jocham, G. Conti, F. Montorsi, H. C. Arentsen, D. Zaak, A. H. Mostafid, and M. Babjuk, "Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations," Eur. Urol. 57(4), 607-614 (2010).
16. S. A. Gross and H. C. Wolfsen, "The role of photodynamic therapy in the esophagus," Gastrointest. Endosc. Clin. N. Am. 20(1), 35-53, vi (2010).
17. M. S. Eljamel, "Brain photodiagnosis (PD), fluorescence guided resection (FGR) and photodynamic therapy (PDT): past, present and future," Photodiagnos. Photodyn. Ther. 5(1), 29-35 (2008).
18. J. Usuda, S. Ichinose, T. Ishizumi, H. Hayashi, K. Ohtani, S. Maehara, S. Ono, N. Kajiwara, O. Uchida, H. Tsutsui, T. Ohira, H. Kato, and N. Ikeda, "Management of multiple primary lung cancer in patients with centrally located early cancer lesions," J. Thorac. Oncol. 5(1), 62-68 (2010).
19. M. Triesscheijn, P. Baas, J. H. Schellens, and F. A. Stewart, "Photody-namic therapy in oncology," Oncologist 11(9), 1034-1044 (2006).
20. T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, and Q. Peng, "Photodynamic therapy," J. Natl. Cancer Inst. 90(12), 889-905 (1998).
21. M. F. Zuluaga and N. Lange, "Combination of photodynamic therapy with anti-cancer agents," Curr. Med. Chem. 15(17), 1655-1673 (2008).
22. S. O. Gollnick, B. Owczarczak, and P. Maier, "Photodynamic therapy and anti-tumor immunity," Lasers Surg. Med. 38(5), 509-515 (2006).
23. M. Korbelik and G. J. Dougherty, "Photodynamic therapy-mediated immune response against subcutaneous mouse tumors," Cancer Res. 59(8), 1941-1946 (1999).
24. E. L. Larsen, L. L. Randeberg, O. A. Gederaas, C. J. Arum, A. Hjelde, C. M. Zhao, D. Chen, H. E. Krokan, and L. O. Svaasand, "Monitoring of hexyl 5-aminolevulinate-induced photodynamic therapy in rat bladder cancer by optical spectroscopy," J. Biomed. Opt. 13(4), 044031 (2008).
25. C. J. Arum, E. Anderssen, K. Tommeras, S. Lundgren, D. Chen, and C. M. Zhao, "Gene expression profiling and pathway analysisofsuperficial bladder cancer in rats," Urology 75(3), 742-749 (2010).
26. K. Hendricksen, J. Molkenboer-Kuenen, E. Oosterwijk, C. A. Hulsbergen-van de Kaa, and J. A. Witjes, "Evaluation of an ortho-topic rat bladder urothelial cell carcinoma model by cystoscopy," BJU Int. 101(7), 889-893 (2008).
27. S. El Khatib, J. Didelon, A. Leroux, L. Bezdetnaya, D. Notter, and M. D'Hallewin, "Kinetics, biodistribution and therapeutic efficacy of hexylester 5-aminolevulinate induced photodynamic therapy in an or-thotopic rat bladder tumor model," J. Urol. 172(5 Pt 1), 2013-2017 (2004).
28. M. Kanehisa, S. Goto, M. Furumichi, M. Tanabe, M. Hirakawa, "KEGG for representation and analysis of molecular networks involving diseases and drugs," Nucl. Acids Res. 38 (Suppl. 1), D355-60 (2010)
29. M. Kanehisa, S. Goto, "KEGG: Kyoto Encyclopaedia of Genes and Genomes," Nucl. Acids Res. 28(1), 27-30 (2000).
30. C. J. Arum, E. Anderssen, T. Viset, Y. Kodama, S. Lundgren, D. Chen, and C. M. Zhao, "Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer," Neoplasia 12(6), 434-442 (2010).
31. R. Oyasu, "Epithelial tumours of the lower urinary tract in humans and rodents," Food Chem. Toxicol. 33(9), 747-755 (1995).
32. P. A. Oliveira, A. Colaco, P. L. De la Cruz, and C. Lopes, "Experimental bladder carcinogenesis-rodent models," Exp. Oncol. 28(1), 2-11 (2006).
33. N. Lange, P. Jichlinski, M. Zellweger, M. Forrer, A. Marti, L. Guillou, P. Kucera, G. Wagnieres, and H. Van Den Bergh, "Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study," Br. J. Cancer 80(1-2), 185-193 (1999).
34. P. Hillemanns, X. Wang, H. Hertel, V. Andikyan, M. Hillemanns, H. Stepp, and P. Soergel, "Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia," Am. J. Obstet. Gynecol. 198(3), 300.e1-300.e7 (2008).
35. S. Gronlund-Pakkanen, T. M. Pakkanen, M. Talja, V. M. Kosma, M. Ala-Opas. and E. Alhava, "The morphological changes in rat bladder after photodynamic therapy with 5-aminolaevulinic acid-induced pro-toporphyrin IX," BJU Int. 86(1), 126-132 (2000).
36. N. Solban, I. Rizvi, and T. Hasan, "Targeted photodynamic therapy," Lasers Surg. Med. 38(5), 522-531 (2006).
37. A. P. Castano, P. Mroz, and M. R. Hamblin, "Photodynamic therapy and anti-tumour immunity," Nat. Rev. Cancer 6(7), 535-545 (2006).
38. R. Hilf, "Mitochondria are targets of photodynamic therapy," J. Bioenerg. Biomembr. 39(1), 85-89 (2007).
39. T. Jung, N. Bader, and T. Grune, "Lipofuscin: formation, distribution, and metabolic consequences," Ann. N.Y. Acad. Sci. 1119, 97-111 (2007).
40. Y. Ohgari, Y. Miyata, T. Thanh Chau, S. Kitajima, Y. Adachi, and S. Taketani, "Quinolone compounds enhance {delta}-aminolevulinic acid (ALA)-induced accumulation of protoporphyrin IX and photosensitiv-ity of tumor cells," J. Biochem. (2010).
41. D. Kessel, M. G. Vicente, and J. J. Reiners, Jr., "Initiation of apoptosis and autophagy by photodynamic therapy," Lasers Surg. Med. 38(5), 482-488 (2006).
42. D. Kessel and J. J. Reiners, Jr., "Apoptosis and autophagy after mito-chondrial or endoplasmic reticulum photodamage," Photochem. Pho-tobiol. 83(5), 1024-1028 (2007).
43. D. Kessel and N. L. Oleinick, "Initiation ofautophagy by photodynamic therapy," Methods Enzymol. 453, 1-16 (2009).
44. R. J. Sylvester, A.P.M. van der Meijden, and D. L. Lamm, "Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials," J. Urol. 168(5), 1964-1970 (2002).
45. R. F. Han and J. G. Pan, "Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials," Urology 67(6), 1216-1223 (2006).
46. D. Lamm, A. Bohle, J. Palou, R. Persad, M. Brausi, M. Colombel, H. Akaza, and R. Buckley, Re: Per-Uno Malmstrom, Richard J. Sylvester, David E. Crawford, P-U. Malmstom, R.J. Sylvester, D.E. Crawford, M. Friedrich, S. Krege, E. Rintala, E. Solsona, S.M. Di Stasi, J. A. Witjes, "An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin c versus bacillus calmette-guerin for non-muscle-invasive bladder cancer" Eur. Urol. 56, 247-256 (2009)
47. Eur. Urol. 57(2), e7-9; author reply e10-11 (2010).
48. D. Jocham, H. Stepp, and R. Waidelich, "Photodynamic diagnosis in urology: state-of-the-art," Eur. Urol. 53(6), 1138-1148 (2008).
49. D. Jocham, J. von Wietersheim, H. Pfluger, H. Steiner, C. Doehn, H. Buttner, A. Bohle, and I. Kausch, "BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer - a multicentre clinical phase III study," Aktuelle Urol. 40(2), 91-99 (2009).